Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jan;84(1):18-24.
doi: 10.1111/bcp.13402. Epub 2017 Oct 10.

Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial

Rosa L de Jager  1 , Erik M van Maarseveen  2 , Michiel L Bots  3 , Peter J Blankestijn  1 ; SYMPATHY investigators
Affiliations
Randomized Controlled Trial

Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial

Rosa L de Jager et al. Br J Clin Pharmacol. 2018 Jan.

Abstract

Aims: Hypertension is only controlled in approximately 35% of the patients, which could be partially due to nonadherence. Recently, bioanalytical assessment of adherence to blood pressure (BP) lowering drugs has gaining interest. Our aim was to explore possible determinants of nonadherence in treatment resistant hypertension, assessed by objective screening for antihypertensive agents in serum. The secondary aim was to study the effect of adherence on the change in BP.

Methods: This project was a substudy of SYMPATHY; an open-label randomized-controlled trial to assess the effect of renal denervation on BP 6 months after treatment compared to usual care in patients with resistant hypertension. Stored serum samples were screened for antihypertensive agents to assess adherence at baseline and 6 months after intervention, using liquid chromatography-tandem mass spectrometry. Office and 24-h BP were measured on the same day as blood was sampled. Patients and physicians were unaware of adherence measurements.

Results: Ninety-eight baseline and 83 6-month samples were available for analysis. Sixty-eight percent [95% confidence interval (CI) 59-78%] of the patients was nonadherent (n = 67). For every onw pill more prescribed, 0.785 [95%CI 0.529-0.891] prescribed pill was less detected in blood. A decrease of one pill in adherence between baseline and 6 months was associated with a significant rise in office systolic BP of 4 (95%CI 0.230-8.932) mmHg.

Conclusion: Objective measurement of BP lowering drugs in serum, as a tool to assess adherence, showed that nonadherence was very common in patients with apparent resistant hypertension. Furthermore, the assessment results were related to (changes in) blood pressure. Our findings provide direct and objective methodology to help the physician to understand and to improve the condition of apparent resistant hypertension.

Keywords: adherence; randomized controlled trial; resistant hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relation between the number of prescribed and the number of detected BP lowering pills in blood at baseline with line of identity (0 = 0, 1 = 1, etc.). One dot represents one patient
Figure 2
Figure 2
Number of patients that was prescribed to different classes of BP lowering drugs and the number of patients in which the prescribed class was detected. BP: blood pressure; RAS: renin‐angiotensin system
Figure 3
Figure 3
The number of patients in which the prescription of BP lowering classes changed at 6 months compared to baseline (e.g. at baseline no diuretics, but, at 6 months, diuretics were prescribed) and the number of patients in which the change in prescription was detected in blood. BP: blood pressure; RAS: renin–angiotensin system
See this image and copyright information in PMC

References

    1. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross‐sectional study from 1994 to 2011. Lancet 2014; 383: 1912–1919. - PubMed
    1. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27: 963–975. - PubMed
    1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990‐2015. JAMA 2017; 317: 165–182. - PubMed
    1. de Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, et al Impact of medication adherence on the effect of renal denervation. The SYMPATHY trial. Hypertension 2017; 69: 678–684. - PubMed
    1. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta‐analysis. Lancet 2016; 387: 957–967. - PubMed

Publication types

Substances

Supplementary concepts